Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer

Table 3

Correlation between CTC and patients’ clinical indicators before neoadjuvant therapy (baseline).

Spearman’s rho			Total CTC	Total CTC(≤7/>7)	Epithelial CTC	Mixed CTC	Mesenchymal CTC	Mesenchymal CTC (≤0/>0)	Mesenchymal CTC proportion
Age (≤60/>60)	N = 41	0.2; 31	0.1; 81	0.1; 83	−0.214	0.23; 7	0.171	0.159	−0.231
		0.1; 27	0.2; 34	0.2; 30	0.158	0.11; 8	0.26	0.297	0.127
T stage (≤3/>3)	N = 45	r	0.0; 82	0.0; 12	0	0.22; 9	−0.138	0.155	0.126
		P	0.5; 93	0.9; 36	1	0.13; 0	0.365	0.308	0.41
N stage	N = 40	r	0.2; 32	0.4; 17	0.279	0.02; 5	0.244	0.092	0.134
		P	0.2; 17	0.0; 22	0.136	0.89; 7	0.193	0.63	0.481
CA-199 (normal/abnormal)	N = 39	r	0.1; 41	0.0; 36	−0.159	0.08; 4	−0.15	0.133	0.156
		P	0.3; 54	0.8; 13	0.298	0.58; 3	0.325	0.385	0.307

When (two-tailed) or (two-tailed), it indicated a significant correlation; CTC, circulating tumor cells.